Time and Date: Thursday, Oct. 22, 2020 at 10am EDT | 3pm BST | 4pm CEST
With the emergence of human induced pluripotent stem cell (hiPSC) technology, it is now possible to design and manufacture CNS cell models such as neurons, astrocytes and microglia that are critical players in
multiple disease pathogenesis. The application of in vitro predictive seizurogenic assays, such as Microelectrode Array (MEA) technology platforms, have been shown to be essential in monitoring and characterizing neuronal spontaneous
activity in diverse neuronal models and to modulate neuronal networks that are crucial to understand seizure patterns and participating pathways.
During this webinar we discuss the advantages, challenges and solutions of generating and implementing hiPSC- derived neuronal models in drug discovery, disease modelling and assay development.
To gain an insight and to better understand the challenges and benefits of hiPSC-derived neuronal models, register for this webinar presented by Ncardia.
Key Learning Objectives:
Understand the benefits and challenges of hiPSC-derived neuronal models
- Gain insight into the generation and optimization of an iPSC cell model and culture system
- See the application of a predictive seizure assay using MEA technology and hiPSC-derived neurons
Steven Dublin, PhD, Head of Product Management
Steven Dublin obtained his PhD in Chemistry from Emory University
in 2007 and subsequently worked as a post-doctoral researcher in
Biomedical Engineering at the Georgia Institute of Technology. With more
than a decade of experience developing and commercializing products at
biotech and large Pharma companies, he is now the Head of Product
Management at Ncardia.
Isabel Onofre, PhD, Cell Development Scientist
Isabel is a cell & disease model development scientist at
Ncardia. She obtained her PhD in Pharmaceutical Biotechnology in 2016,
and subsequently worked as a post-doctoral researcher at Sanford Burnham
Prebys Medical Discovery Institute. Isabel has extensive experience in
modelling human neurodegenerative diseases in iPSC-derived neurons and
the development of predictive seizurogenic assays on MEA.